Abstract

You have accessJournal of UrologyBladder Cancer: Upper Tract Transitional Cell Carcinoma I1 Apr 2018MP18-10 STAT3 EXPRESSION IS A PROGNOSTIC MARKER IN UPPER URINARY TRACT UROTHELIAL CARCINOMA Kazutoshi Fujita, Kyosuke Matsuzaki, Satoshi Nojima, Kentaro Jingushi, Taigo Kato, Atsushi Kawashima, Takeshi Ujike, Akira Nagahara, Motohide Uemura, Seiji Yamaguchi, Hiroaki Fushimi, Eiji Morii, Hiroshi Miyamoto, Ryoichi Imamura, and Norio Nonomura Kazutoshi FujitaKazutoshi Fujita More articles by this author , Kyosuke MatsuzakiKyosuke Matsuzaki More articles by this author , Satoshi NojimaSatoshi Nojima More articles by this author , Kentaro JingushiKentaro Jingushi More articles by this author , Taigo KatoTaigo Kato More articles by this author , Atsushi KawashimaAtsushi Kawashima More articles by this author , Takeshi UjikeTakeshi Ujike More articles by this author , Akira NagaharaAkira Nagahara More articles by this author , Motohide UemuraMotohide Uemura More articles by this author , Seiji YamaguchiSeiji Yamaguchi More articles by this author , Hiroaki FushimiHiroaki Fushimi More articles by this author , Eiji MoriiEiji Morii More articles by this author , Hiroshi MiyamotoHiroshi Miyamoto More articles by this author , Ryoichi ImamuraRyoichi Imamura More articles by this author , and Norio NonomuraNorio Nonomura More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.586AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Signal transducer and activator of transcription 3 (STAT3) plays a prominent role in the growth and invasion of several types of solid tumors. STAT3 are activated via Sphingosine-1-phosphate receptor 1(S1PR1) or IL-6. In this study, we evaluated the expression status of STAT3 pathway proteins, STAT3, S1PR1, and IL-6, in upper urinary tract urothelial carcinoma (UTUC) and analyzed their prognostic significance. METHODS A UTUC tissue microarray (TMA) was constructed with spotted triplicate tumor samples from 99 patients who underwent radical nephroureterectomy performed. Immunohistochemical staining was performed on using a primary antibody to STAT3, S1PR1 and IL-6. RESULTS There were no significant associations between STAT3, S1PR1, or IL-6 expression pattern and tumor grade or pT stage. However, the patients with high STAT3 tumor had a significantly higher risk of both disease progression (p=0.009) and cancer-specific mortality (p=0.009) than those with low STAT3 tumor. High STAT3 expression in the nucleus was also associated with a significantly higher risk of both disease progression (p=0.003) and cancer-specific mortality (p=0.034). Multivariate analysis revealed that high STAT3 expression in the nucleus was significantly associated with cancer-specific survival after adjustment for pathological stage, lymph node involvement, lymphovascular invasion, and tumor grade (HR=2.136, 95% CI=1.009-4.767, p=0.047). CONCLUSIONS Our findings indicated that STAT3 could be a cancer-promoting factor and potentially a significant prognostic factor in UTUC. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e216-e217 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Kazutoshi Fujita More articles by this author Kyosuke Matsuzaki More articles by this author Satoshi Nojima More articles by this author Kentaro Jingushi More articles by this author Taigo Kato More articles by this author Atsushi Kawashima More articles by this author Takeshi Ujike More articles by this author Akira Nagahara More articles by this author Motohide Uemura More articles by this author Seiji Yamaguchi More articles by this author Hiroaki Fushimi More articles by this author Eiji Morii More articles by this author Hiroshi Miyamoto More articles by this author Ryoichi Imamura More articles by this author Norio Nonomura More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.